Leroy Merlin Enriches the Customer Experience With Hanshow Digital Solutions
7.6.2024 11:30:00 EEST | Business Wire | Press release
Hanshow, a leader in Electronic Shelf Labels (ESLs) and digital retail solutions, and Leroy Merlin, a global DIY leader, have partnered to enhance customer and employee experiences by deploying ESLs across over 50,000 products integrated with the Leroy Merlin mobile app in France. Customers now enjoy seamless shopping with easy product geolocation and personalized recommendations in Leroy Merlin stores. After 18 months of R&D, they implemented a fully customized solution in all Leroy Merlin outlets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604438443/en/
Hanshow's ESL Solution at Leroy Merlin. (Graphic: Business Wire)
Enhanced Customer Support with Leroy Merlin's Mobile Application
This immersive experience is powered by the Leroy Merlin mobile application in conjunction with Hanshow's state-of-the-art ESL solutions. Leroy Merlin’s integration of Hanshow ESL into its app offers geolocation in-store to guide customers to products and aisles. This enhances the shopping experience and allows staff to provide more personalized advice and support.
The ESL solution also provides price consistency between online and offline channels, enriching user experience with various features such as customer reviews, enriched product descriptions, access the Home Index to assess a product's environmental and social impact, and the ability to flash labels directly from the application. These functions provide flexibility for consumers and store associates.
"We have successfully met the expectations of Leroy Merlin customers by developing a solution that enhances the in-store experience. By combining data and technological innovations, we have created a tailor-made tool that delivers a personalized experience for each customer," explains Pierre Fosseux, VP of Hanshow France.
Enhancing Retail Efficiency and Customer Experience
Whether it's stock management, restocking, or click-and-collect order preparation, the geolocation of products in the shop is a real time-saver for staff, who can devote themselves to focusing on higher-value tasks. "It now takes sales staff around 75 seconds to pick up a product, instead of 90 seconds previously, for orders placed online and picked up in the shop within a two-hour window chosen by the customer," says Olivier Personne, Merchandising Optimization Manager at Leroy Merlin. Eliminating price differences has positively improved customer satisfaction.
"The solution co-constructed with Hanshow enriches the customer experience across online and offline channels while simplifying in-store team tasks. Currently deployed in France, it is designed for larger-scale rollout in other Leroy Merlin locations," explains Hugues Hartung de la Roer, Concept & Merchandising Director at Leroy Merlin France.
Exemplifying both companies' commitment to enhancing customer satisfaction and driving innovation in the retail sector, the new solution not only simplifies the shopping process but also provides valuable data insights to improve store operations and customer engagement.
The collaboration won the Reta Awards 2024: Best In-store Solution for Leroy Merlin and Top Supplier for Hanshow, for transforming the retail environment with advanced technology.
About Leroy Merlin France
A pioneering company in the Adeo Group, Leroy Merlin is now the leading brand in France in all distribution channels for improving the home and the living environment. Specialising in the sale of products, projects and services, Leroy Merlin France has set itself the goal of building new ways of living with everyone, so that we can live better in the future, and puts customer satisfaction at the heart of its business.
About Hanshow
Hanshow is one of the global leaders in the development and manufacturing of electronic shelf labels and digital store solutions . The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores across more than 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604438443/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom